Targeted Therapy for Nasopharyngeal Cancer
Cetuximab (Erbitux) is a drug that targets EGFR and can be used to treat some nasopharyngeal cancers.
Bizonyítékszint: Korai humán adat. Kis vagy feltáró emberi adat.
Kapcsolódó jelek
- Anti‑PD‑1 antibody penpulimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: a randomized, double‑blind phase 3 study
- Advances in targeted therapy mainly based on signal pathways for nasopharyngeal carcinoma
- Nasopharyngeal Cancer
- Hierarchical dynamic model for risk‑stratified screening of nasopharyngeal carcinoma
- Expert consensus on the role of immunotherapy in nasopharyngeal carcinoma: clinical and economic perspectives from the GCC region